SAB Biotherapeutics Inc (SABS) — Capital Reinvestment Ratio

Latest as of December 2022: 0.54x

SAB Biotherapeutics Inc (SABS) has a Capital Reinvestment Ratio of 0.54x as of December 2022, meaning it reinvests 1% of its operating cash flow ($216.72K) in capital expenditures ($117.75K). Check SABS goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.54x
Capex / Operating Cash Flow

Operating Cash Flow

$216.72K
USD

Capital Expenditures

$117.75K
USD

Data as of

Dec 2022
Most recent filing

SAB Biotherapeutics Inc Capital Reinvestment Ratio (2020–2021)

This chart tracks SAB Biotherapeutics Inc's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see SAB Biotherapeutics Inc (SABS) cash conversion ratio.

Annual Capital Reinvestment Ratio for SAB Biotherapeutics Inc (2020–2021)

Year-by-year Capital Reinvestment Ratio for SAB Biotherapeutics Inc from 2020 to 2021. See SABS free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2021 5.51x $1.99 Million $10.94 Million ▲ +332.8%
2020 1.27x $10.00 Million $12.73 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow